RS61359B1 - Postupci i sastavi vezani za upotrebu surfaktanata sa niskom hlb u proizvodnji sintetičkih nano nosača koji sadrže rapalog - Google Patents
Postupci i sastavi vezani za upotrebu surfaktanata sa niskom hlb u proizvodnji sintetičkih nano nosača koji sadrže rapalogInfo
- Publication number
- RS61359B1 RS61359B1 RS20210097A RSP20210097A RS61359B1 RS 61359 B1 RS61359 B1 RS 61359B1 RS 20210097 A RS20210097 A RS 20210097A RS P20210097 A RSP20210097 A RS P20210097A RS 61359 B1 RS61359 B1 RS 61359B1
- Authority
- RS
- Serbia
- Prior art keywords
- nonionic surfactant
- equal
- hlb value
- value less
- synthetic nanocarriers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cosmetics (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075864P | 2014-11-05 | 2014-11-05 | |
| US201462075866P | 2014-11-05 | 2014-11-05 | |
| EP15798601.9A EP3215133B1 (en) | 2014-11-05 | 2015-11-05 | Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog |
| PCT/US2015/059349 WO2016073798A1 (en) | 2014-11-05 | 2015-11-05 | Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61359B1 true RS61359B1 (sr) | 2021-02-26 |
Family
ID=54697646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210097A RS61359B1 (sr) | 2014-11-05 | 2015-11-05 | Postupci i sastavi vezani za upotrebu surfaktanata sa niskom hlb u proizvodnji sintetičkih nano nosača koji sadrže rapalog |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20160128986A1 (OSRAM) |
| EP (6) | EP3906918B1 (OSRAM) |
| JP (5) | JP7218089B2 (OSRAM) |
| KR (2) | KR102656139B1 (OSRAM) |
| CN (5) | CN115212186A (OSRAM) |
| AU (4) | AU2015342968B2 (OSRAM) |
| BR (3) | BR122021025344B1 (OSRAM) |
| CA (2) | CA2966850C (OSRAM) |
| CY (1) | CY1124418T1 (OSRAM) |
| DK (4) | DK3215133T3 (OSRAM) |
| EA (2) | EA201790977A1 (OSRAM) |
| ES (4) | ES2846809T3 (OSRAM) |
| FI (2) | FI3834823T3 (OSRAM) |
| HR (1) | HRP20210098T1 (OSRAM) |
| HU (4) | HUE066099T2 (OSRAM) |
| IL (7) | IL283699B (OSRAM) |
| LT (1) | LT3215133T (OSRAM) |
| MX (4) | MX383295B (OSRAM) |
| PL (1) | PL3215133T3 (OSRAM) |
| PT (1) | PT3215133T (OSRAM) |
| RS (1) | RS61359B1 (OSRAM) |
| SI (1) | SI3215133T1 (OSRAM) |
| WO (2) | WO2016073798A1 (OSRAM) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2435094A2 (en) | 2009-05-27 | 2012-04-04 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| CA2798323A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| CN104623666A (zh) | 2011-04-29 | 2015-05-20 | 西莱克塔生物科技公司 | 用于诱导调节性b细胞的致耐受性合成纳米载体 |
| MX2014001142A (es) | 2011-07-29 | 2014-02-27 | Selecta Biosciences Inc | Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl). |
| MX380164B (es) | 2013-05-03 | 2025-03-12 | Selecta Biosciences Inc | Uso de una macromolécula terapéutica y una composición que comprende nanoportadores sintéticos que se unen a inmunosupresores para reducir la hipersensibilidad tipo i y tipo iv en un sujeto. |
| WO2015025538A1 (ja) * | 2013-08-20 | 2015-02-26 | サンノプコ株式会社 | バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法 |
| IL292574A (en) | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| WO2016132760A1 (ja) * | 2015-02-17 | 2016-08-25 | サンノプコ株式会社 | バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法 |
| WO2016176462A1 (en) | 2015-04-28 | 2016-11-03 | University Of Central Florida Foundation, Inc. | Methods and compositions for theranostic nanoparticles |
| CN109152819A (zh) | 2016-03-11 | 2019-01-04 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
| KR102341902B1 (ko) * | 2016-09-09 | 2021-12-21 | 카오카부시키가이샤 | 디카르복실산 결정 및 그 제조 방법 |
| CA3038089A1 (en) | 2016-09-27 | 2018-04-05 | Selecta Biosciences, Inc. | Recombinant immunotoxins for use in the treatment of cancer |
| BR112019013862A2 (pt) | 2017-01-07 | 2020-04-14 | Selecta Biosciences Inc | dosagem padrão de imunossupressores acoplados a nanocarreadores sintéticos |
| WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| KR20200086670A (ko) | 2017-10-13 | 2020-07-17 | 셀렉타 바이오사이언시즈, 인크. | 항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물 |
| MA54826A (fr) * | 2019-01-24 | 2021-12-01 | Generation Bio Co | Adn à extrémité fermée (cedna) et utilisation dans des procédés de réduction de la réponse immunitaire liée à une thérapie génique ou à acide nucléique |
| KR20220004121A (ko) | 2019-04-28 | 2022-01-11 | 셀렉타 바이오사이언시즈, 인크. | 바이러스 전달 벡터에 대한 기존의 면역을 갖는 대상체의 치료 방법 |
| CN114206396A (zh) | 2019-05-28 | 2022-03-18 | 西莱克塔生物科技公司 | 用于减弱抗病毒转移载体免疫应答的方法和组合物 |
| EP3980784A1 (en) | 2019-06-04 | 2022-04-13 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
| JP2022553345A (ja) * | 2019-10-21 | 2022-12-22 | セレクタ バイオサイエンシーズ インコーポレーテッド | 肝疾患および肝障害を処置するための方法および組成物 |
| CA3160642A1 (en) | 2019-11-08 | 2021-05-14 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
| CA3173734A1 (en) | 2020-02-26 | 2021-09-02 | Selecta Biosciences, Inc. | Methods and compositions using synthetic nanocarriers comprising immunosuppressant |
| IL296326A (en) * | 2020-03-11 | 2022-11-01 | Selecta Biosciences Inc | Methods and compositions related to synthetic nanocarriers |
| IL297274A (en) | 2020-04-14 | 2022-12-01 | Selecta Biosciences Inc | Methods and compositions for inducing autophagy |
| JP2023548601A (ja) | 2020-11-04 | 2023-11-17 | セレクタ バイオサイエンシーズ インコーポレーテッド | 免疫グロブリンプロテアーゼに対する免疫応答を低減するための組成物 |
| WO2022150335A1 (en) | 2021-01-05 | 2022-07-14 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| KR102304785B1 (ko) | 2021-03-26 | 2021-09-24 | (주)진성티앤피 | 정밀광학기기의 부품 제조 방법 |
| US20220323607A1 (en) | 2021-04-09 | 2022-10-13 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| EP4415760A1 (en) | 2021-10-12 | 2024-08-21 | Cartesian Therapeutics, Inc. | Viral vector dosing protocols |
| WO2023086615A1 (en) | 2021-11-14 | 2023-05-19 | Selecta Biosciences, Inc. | Multiple dosing with viral vectors |
| WO2023133319A1 (en) | 2022-01-10 | 2023-07-13 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| WO2023172628A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| US20230381277A1 (en) | 2022-04-08 | 2023-11-30 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| AU2023321906A1 (en) | 2022-08-11 | 2025-03-27 | Cartesian Therapeutics, Inc. | Compositions and methods related to immunoglobulin proteases and fusions thereof |
| WO2024107889A1 (en) | 2022-11-15 | 2024-05-23 | Selecta Biosciences, Inc. | Compositions and methods for treating primary biliary cholangitis |
| WO2024229432A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| WO2024229350A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes |
| WO2024229380A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases |
| WO2024229370A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Compositions and methods for treating gvhd |
| TWI877967B (zh) * | 2023-12-28 | 2025-03-21 | 訊聯生物科技股份有限公司 | 包含小分子核糖核酸及奈米載體之組合物、包含其的醫藥組成物及其用途 |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US7288266B2 (en) | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| WO2000006120A1 (en) | 1998-07-31 | 2000-02-10 | Korea Institute Of Science And Technology | Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier |
| EP1107783B1 (en) * | 1998-09-01 | 2006-04-05 | ELAN CORPORATION, Plc | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
| HK1048772A1 (zh) | 2000-02-28 | 2003-04-17 | Genesegues, Inc. | 纳米胶囊包封系统与方法 |
| US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| WO2004017943A2 (en) | 2002-08-23 | 2004-03-04 | Medigene Oncology Gmbh | Non-vesicular cationic lipid formulations |
| CN1886100A (zh) * | 2003-11-14 | 2006-12-27 | 阿尔萨公司 | 基于表面活性剂的凝胶作为可注射的持续药物递送载体 |
| US20050260260A1 (en) | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
| CA2620389C (en) * | 2005-08-31 | 2014-06-17 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US8414910B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| CA2917512C (en) | 2007-10-12 | 2025-08-05 | President And Fellows Of Harvard College | VACCINE NANOTECHNOLOGY |
| WO2010005726A2 (en) * | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| EP2309990B2 (en) * | 2008-06-16 | 2017-03-15 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| JP2012512175A (ja) * | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| WO2012035074A1 (en) * | 2010-09-14 | 2012-03-22 | Nanologica Ab | Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients |
| WO2012059936A1 (en) * | 2010-11-03 | 2012-05-10 | Padma Venkitachalam Devarajan | Pharmaceutical compositions for colloidal drug delivery |
| CN104623666A (zh) * | 2011-04-29 | 2015-05-20 | 西莱克塔生物科技公司 | 用于诱导调节性b细胞的致耐受性合成纳米载体 |
| CN102793674B (zh) * | 2011-05-26 | 2014-11-26 | 澳门科技大学 | 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用 |
| BR112014008932A2 (pt) | 2011-10-14 | 2019-09-24 | Sandia Corp | bicamadas lipídicas suportadas em nanopartículas porosas (protocélulas) para administração direcionada, incluindo a administração transdérmica de uma carga e métodos associados |
| TWI439288B (zh) * | 2012-10-05 | 2014-06-01 | Univ China Medical | 藥用載體及其製備方法與用途 |
| CN102871966B (zh) * | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
-
2015
- 2015-11-05 EA EA201790977A patent/EA201790977A1/ru unknown
- 2015-11-05 MX MX2017005903A patent/MX383295B/es unknown
- 2015-11-05 AU AU2015342968A patent/AU2015342968B2/en active Active
- 2015-11-05 IL IL283699A patent/IL283699B/en unknown
- 2015-11-05 KR KR1020177014830A patent/KR102656139B1/ko active Active
- 2015-11-05 FI FIEP20204014.3T patent/FI3834823T3/fi active
- 2015-11-05 CA CA2966850A patent/CA2966850C/en active Active
- 2015-11-05 DK DK15798601.9T patent/DK3215133T3/da active
- 2015-11-05 LT LTEP15798601.9T patent/LT3215133T/lt unknown
- 2015-11-05 US US14/934,132 patent/US20160128986A1/en active Pending
- 2015-11-05 PL PL15798601T patent/PL3215133T3/pl unknown
- 2015-11-05 CA CA2966852A patent/CA2966852C/en active Active
- 2015-11-05 EP EP21156943.9A patent/EP3906918B1/en active Active
- 2015-11-05 CN CN202210754468.4A patent/CN115212186A/zh active Pending
- 2015-11-05 IL IL295292A patent/IL295292B2/en unknown
- 2015-11-05 ES ES15798601T patent/ES2846809T3/es active Active
- 2015-11-05 ES ES20204014T patent/ES2977158T3/es active Active
- 2015-11-05 EP EP23220845.4A patent/EP4356910A3/en not_active Withdrawn
- 2015-11-05 RS RS20210097A patent/RS61359B1/sr unknown
- 2015-11-05 CN CN202110403075.4A patent/CN113244191A/zh active Pending
- 2015-11-05 EP EP23220853.8A patent/EP4360633A3/en not_active Withdrawn
- 2015-11-05 HR HRP20210098TT patent/HRP20210098T1/hr unknown
- 2015-11-05 EP EP15798601.9A patent/EP3215133B1/en active Active
- 2015-11-05 KR KR1020177014831A patent/KR102601922B1/ko active Active
- 2015-11-05 US US14/934,135 patent/US20160128987A1/en not_active Abandoned
- 2015-11-05 ES ES15857076T patent/ES2865375T3/es active Active
- 2015-11-05 WO PCT/US2015/059349 patent/WO2016073798A1/en not_active Ceased
- 2015-11-05 WO PCT/US2015/059350 patent/WO2016073799A1/en not_active Ceased
- 2015-11-05 HU HUE20204014A patent/HUE066099T2/hu unknown
- 2015-11-05 HU HUE15798601A patent/HUE053094T2/hu unknown
- 2015-11-05 PT PT157986019T patent/PT3215133T/pt unknown
- 2015-11-05 EA EA201790978A patent/EA201790978A1/ru unknown
- 2015-11-05 DK DK20204014.3T patent/DK3834823T3/da active
- 2015-11-05 AU AU2015342969A patent/AU2015342969B2/en active Active
- 2015-11-05 HU HUE21156943A patent/HUE067697T2/hu unknown
- 2015-11-05 BR BR122021025344-7A patent/BR122021025344B1/pt active IP Right Grant
- 2015-11-05 HU HUE15857076A patent/HUE054894T2/hu unknown
- 2015-11-05 BR BR112017008720A patent/BR112017008720A2/pt not_active Application Discontinuation
- 2015-11-05 FI FIEP21156943.9T patent/FI3906918T3/fi active
- 2015-11-05 EP EP20204014.3A patent/EP3834823B1/en active Active
- 2015-11-05 DK DK21156943.9T patent/DK3906918T3/da active
- 2015-11-05 CN CN201580060789.2A patent/CN107072965B/zh active Active
- 2015-11-05 ES ES21156943T patent/ES2977259T3/es active Active
- 2015-11-05 MX MX2017005904A patent/MX386982B/es unknown
- 2015-11-05 CN CN201580059855.4A patent/CN107072964A/zh active Pending
- 2015-11-05 IL IL296246A patent/IL296246A/en unknown
- 2015-11-05 EP EP15857076.2A patent/EP3215192B1/en active Active
- 2015-11-05 SI SI201531494T patent/SI3215133T1/sl unknown
- 2015-11-05 CN CN202210754573.8A patent/CN115212187A/zh active Pending
- 2015-11-05 DK DK15857076.2T patent/DK3215192T3/da active
- 2015-11-05 JP JP2017524451A patent/JP7218089B2/ja active Active
- 2015-11-05 BR BR112017008499-6A patent/BR112017008499B1/pt active IP Right Grant
- 2015-11-05 JP JP2017524450A patent/JP6912377B2/ja active Active
-
2017
- 2017-04-06 IL IL251620A patent/IL251620B/en active IP Right Grant
- 2017-04-06 IL IL251622A patent/IL251622B/en active IP Right Grant
- 2017-05-04 MX MX2021006698A patent/MX2021006698A/es unknown
- 2017-05-04 MX MX2021012273A patent/MX2021012273A/es unknown
-
2021
- 2021-01-27 CY CY20211100063T patent/CY1124418T1/el unknown
- 2021-01-31 IL IL280518A patent/IL280518B/en unknown
- 2021-05-10 JP JP2021080003A patent/JP2021143180A/ja active Pending
- 2021-07-27 AU AU2021209204A patent/AU2021209204A1/en not_active Abandoned
- 2021-07-27 AU AU2021209202A patent/AU2021209202B2/en active Active
- 2021-12-02 IL IL288609A patent/IL288609B2/en unknown
-
2022
- 2022-09-01 JP JP2022139392A patent/JP2022173236A/ja active Pending
-
2023
- 2023-07-03 JP JP2023109379A patent/JP2023169893A/ja active Pending
-
2024
- 2024-10-21 US US18/921,868 patent/US20250152561A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021209202B2 (en) | Methods and compositions related to the use of low HLB surfactants in the production of synthetic nanocarriers comprising a rapalog | |
| KR20220152263A (ko) | 합성 나노담체와 관련된 방법 및 조성물 | |
| BR122023013695B1 (pt) | Composições compreendendo nanoveículos sintéticos, seus usos, método para produzir os mesmos e kit |